BioSpace News Archive

The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.

The company aims to treat different forms of mental illness and brain disorders with its pipeline.

− Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced the completion of a Pre-Investigational New Drug process following receipt of written comments from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies.

CareDx, Inc. announced that it will share the latest data on AlloSeq Tx17 and AlloSeq HCT at the 47th annual meeting of The American Society for Histocompatibility and Immunogenetics.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announces the acceptance and details of an oral presentation at the American College of Rheumatology Convergence 2021.

Vivex Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, will be attending the North American Spine Society’s (NASS) 36th annual meeting at the Boston Convention and Exhibition Center from Sept. 29 to Oct. 2, 2021.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab”), today announced a research collaboration with Leeds University to further study the role of CCL24 in the vascular damage associated with systemic sclerosis (SSc), a rare rheumatic disease with high morbidity and mortality.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in multiple system atrophy (MSA).

Moleculin Biotech, Inc. today announced that Walter Klemp President and Chief Executive Officer of Moleculin, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:40 AM ET.

Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD (AAVIATE ® ) to be presented REGENXBIO to host conference call and webcast to review the interim data from the AAVIATE trial on Friday, October 1, 2021 , at 5:00 p.m. ET